Guggenheim analyst Debjit Chattopadhyay raised his 2023 revenue estimate for Ionis Pharmaceuticals to $566M from $463M to account for greater collaboration revenue from ongoing mid-to-late stage studies as well as joint development revenue. The analyst, who anticipates the approvals of tofersen and eplontersen in 2023, keeps a Buy rating on Ionis shares with a $64 price target.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on IONS:
- Ionis assumed with Equal Weight from Overweight at Morgan Stanley
- Piper recommends ‘down market cap’ biotech exposure for 2023
- Ionis Pharmaceuticals: EMA accepts MAA for review of tofersen
- Ionis Pharmaceuticals, Metagenomi enter gene editing collaboration
- Ionis presents Phase 2 data from open label extension study of donidalorsen
